Tag Archive for: Appointment

Domain Therapeutics Appoints Boston-Based Pharma Leader Jean-Marie Cuillerot, M.D., as Chief Medical Officer

/in

Internationally recognized clinical strategist with proven track record in translating innovation into clinical impact joins Domain to advance its GPCR-targeting pipeline Appointment comes at a pivotal moment, following the initiation of Phase I/II development of DT-7012, a Treg-depleting anti-CCR8 antibody candidate Strasbourg, France – Montreal, Canada – Boston, United States, November 13, 2025: Domain Therapeutics […]

Read more

Blue Cell Therapeutics appoints leading cell therapy executive Miguel Forte MD, PhD, to its Board of Directors

/in

Miguel Forte, current President of the International Society for Cell & Gene Therapy (ISCT), joins Blue Cell as a Non-Executive Director Highly experienced executive with deep scientific expertise, who has helped lead numerous private and public cell therapy biotechs, establishing corporate structures and raising funds Appointment comes as Blue Cell advances its groundbreaking “off-the-shelf” allogeneic […]

Read more

Amber Implants Appoints Vincent Gardès as Chief Executive Officer to Drive Commercial Launch of VCFix® Spinal System

/in

Experienced MedTech leader to guide Amber Implants’ transition from development into commercialization following  FDA clearance of the VCFix® Spinal System Company preparing for U.S. market launch in 2026 THE HAGUE, The Netherlands, Nov. 6, 2025 /PRNewswire/ — Amber Implants, an innovative medical technology company developing next-generation implants for spinal injuries, today announced the appointment of Vincent Gardès as Chief Executive […]

Read more

Resolution Therapeutics appoints Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer

/in

Highly experienced Chief Financial Officer set to drive corporate and strategic goals of Resolution. Accomplished Chief Business Officer will drive business development and partnering deals. Appointments follow the announcement of the first patient dosed and safety cleared in its Phase I/II EMERALD study. Edinburgh and London, UK 10 September 2025 – Resolution Therapeutics (“Resolution” or “Company”), a clinical-stage biopharmaceutical […]

Read more

Blue Cell Therapeutics appoints highly experienced pharma and biotech executive Olav Hellebø as Chairman of the Board of Directors

/in

Seasoned executive with three decades of experience in pharma and biotech Biotech board experience from Cytovation ASA, Antev Ltd, and Calliditas Therapeutics, and governance / senior leadership experience from UCB, Novartis and Schering-Plough (now Merck) Appointment comes as Blue Cell looks to progress its lead candidate, allogeneic stem cell treatment BlueC-231, into Phase 1/2a clinical […]

Read more